Clinical Trial Update: Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 randomized, open-label, multicenter trial evaluating SHR-2173 for primary membranous nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• SHR-2173

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Primary Membranous Nephropathy | Phase 2 | Status: RECRUITING